002422 科伦药业
已收盘 12-05 15:00:00
资讯
新帖
简况
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
证券之星 · 12-04 20:11
科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
美股速递 · 12-04 19:32
Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
美股速递 · 12-04 19:32
Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
美股速递 · 12-04 19:30
科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
证券之星 · 11-15
科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
证券之星 · 11-14
科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药
科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%
证券之星 · 11-12
科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%
科伦药业：通过互动易平台回应市场关切
证券之星 · 11-10
科伦药业：通过互动易平台回应市场关切
四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元
智通财经 · 11-04
四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元
科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定
证券之星 · 11-04
科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定
科伦药业（002422）2025年三季报简析：净利润同比下降51.41%
证券之星 · 11-01
科伦药业（002422）2025年三季报简析：净利润同比下降51.41%
科伦药业：历年分红累计超IPO融资总额
证券之星 · 10-31
科伦药业：历年分红累计超IPO融资总额
科伦药业最新公告：前三季度净利润同比下降51.41%
证券之星 · 10-30
科伦药业最新公告：前三季度净利润同比下降51.41%
科伦药业最新公告：参与全国药品集中采购拟中标
证券之星 · 10-28
科伦药业最新公告：参与全国药品集中采购拟中标
科伦药业(002422.SZ)：博度曲妥珠单抗治疗2L+ HER2+乳腺癌获批准上市
智通财经 · 10-17
科伦药业(002422.SZ)：博度曲妥珠单抗治疗2L+ HER2+乳腺癌获批准上市
科伦药业(002422.SZ)：罗替高汀贴片获药品注册批准
智通财经 · 10-17
科伦药业(002422.SZ)：罗替高汀贴片获药品注册批准
股市必读：科伦药业（002422）10月15日董秘有最新回复
证券之星 · 10-16
股市必读：科伦药业（002422）10月15日董秘有最新回复
科伦药业（002422）披露2025年度中期分红派息实施公告，10月14日股价下跌2.1%
证券之星 · 10-14
科伦药业（002422）披露2025年度中期分红派息实施公告，10月14日股价下跌2.1%
科伦药业最新公告：子公司核心产品TROP2 ADC芦康沙妥珠单抗获国家药监局批准第三项适应症
证券之星 · 10-12
科伦药业最新公告：子公司核心产品TROP2 ADC芦康沙妥珠单抗获国家药监局批准第三项适应症
川宁生物新注册《科伦药业订单管理系统V1.3》项目的软件著作权
证券之星 · 10-11
川宁生物新注册《科伦药业订单管理系统V1.3》项目的软件著作权
加载更多
公司概况
公司名称：
四川科伦药业股份有限公司
所属行业：
医药制造业
上市日期：
2010-06-03
主营业务：
四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。
发行价格：
83.36
{"stockData":{"symbol":"002422","market":"SZ","secType":"STK","nameCN":"科伦药业","latestPrice":33.73,"timestamp":1764918216000,"preClose":34.1,"halted":0,"volume":8016810,"delay":0,"changeRate":-0.0109,"floatShares":1306000000,"shares":1598000000,"eps":1.0423,"marketStatus":"已收盘","change":-0.37,"latestTime":"12-05 15:00:00","open":34.29,"high":34.35,"low":33.24,"amount":269000000,"amplitude":0.0326,"askPrice":33.74,"askSize":2,"bidPrice":33.73,"bidSize":155,"shortable":0,"etf":0,"ttmEps":1.0423,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765157400000},"marketStatusCode":5,"adr":0,"adjPreClose":34.1,"symbolType":"stock","openAndCloseTimeList":[[1764898200000,1764905400000],[1764910800000,1764918000000]],"highLimit":37.51,"lowLimit":30.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1598053372,"isCdr":false,"pbRate":2.3,"roa":"--","peRate":32.361124,"roe":"5.18%","epsLYR":1.86,"committee":-0.145907,"marketValue":53902000000,"turnoverRate":0.0061,"status":1,"floatMarketCap":44048000000},"requestUrl":"/m/hq/s/002422","defaultTab":"news","newsList":[{"id":"2588889788","title":"科伦药业最新公告：科伦博泰与CrescentBiopharma建立战略合作伙伴关系涉及科伦博泰的SKB105和Crescent的CR-001两款候选药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2588889788","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588889788?lang=zh_cn&edition=full","pubTime":"2025-12-04 20:11","pubTimestamp":1764850275,"startTime":"0","endTime":"0","summary":"科伦药业公告称，公司控股子公司科伦博泰与Crescent Biopharma建立战略合作伙伴关系，共同开发和商业化肿瘤治疗手段。合作涉及两款候选药物：科伦博泰的SKB105和Crescent的CR-001。科伦博泰授予Crescent在美国、欧洲及大中华地区以外市场开发SKB105的独家权利，而Crescent授予科伦博泰在大中华地区开发CR-001的独家权利。科伦博泰将向Crescent收取8000万美元首付款，并有机会获得高达12.5亿美元的里程碑付款。同时，科伦博泰通过此次合作引入CR-001补充和加强了其差异化的肿瘤研发管线。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120400035319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","002422","LU1064130708.USD","BK0239","LU1064131003.USD","LU1979443071.USD","BK0060","LU2148510915.USD"],"gpt_icon":0},{"id":"1115537632","title":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1115537632","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115537632?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847944,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 将获得2000万美元的预付款，以及来自科伦博泰生物的最高3000万美元的额外里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0196878994.USD","LU2148510915.USD","BK0239","06990","LU1064130708.USD","002422","LU1064131003.USD","BK4139","LU1934453819.USD","BK1161","LU1979443071.USD","CBIO","BK0060"],"gpt_icon":0},{"id":"1126942018","title":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1126942018","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126942018?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:32","pubTimestamp":1764847941,"startTime":"0","endTime":"0","summary":"Crescent Biopharma Inc - 科伦博泰生物-B将获得8000万美元的预付款，以及来自Crescent的最高达12.5亿美元的额外里程碑付款","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06990","LU0196878994.USD","002422","LU1064131003.USD","LU1934453819.USD","BK0239","BK1161","CBIO","LU1064130708.USD","LU2148510915.USD","LU1979443071.USD","BK0060"],"gpt_icon":0},{"id":"1115079280","title":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1115079280","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115079280?lang=zh_cn&edition=full","pubTime":"2025-12-04 19:30","pubTimestamp":1764847815,"startTime":"0","endTime":"0","summary":"科伦药业与Crescent Biopharma达成战略合作，共同开发及商业化新型抗肿瘤疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","BK0239","BK4139","CBIO","LU1979443071.USD","LU1934453819.USD","LU0196878994.USD","LU2148510915.USD","LU1064130708.USD","002422","BK0060","06990","BK1161"],"gpt_icon":0},{"id":"2583177683","title":"科伦药业新注册《科伦悦签小程序系统1.0》等2个项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2583177683","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583177683?lang=zh_cn&edition=full","pubTime":"2025-11-15 00:30","pubTimestamp":1763137838,"startTime":"0","endTime":"0","summary":"证券之星消息，近日科伦药业新注册了2个项目的软件著作权，包括《科伦悦签小程序系统1.0》、《科伦安行通小程序系统1.0》等。今年以来科伦药业新注册软件著作权4个，较去年同期增加了100%。通过天眼查大数据分析，四川科伦药业股份有限公司共对外投资了47家企业，参与招投标项目8624次；财产线索方面有商标信息1138条，专利信息2046条，著作权信息14条；此外企业还拥有行政许可1186个。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111500000187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK0239","BK0060","LU1064131003.USD","LU1064130708.USD","002422","LU1934453819.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2583083415","title":"科伦药业最新公告：棕榈酸帕利哌酮注射液获得药品注册批准为全球首个获批的每月给药一次的长效非典型抗精神病药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583083415","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583083415?lang=zh_cn&edition=full","pubTime":"2025-11-14 19:39","pubTimestamp":1763120381,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司子公司湖南科伦制药有限公司的化学药品“棕榈酸帕利哌酮注射液”近日获得国家药品监督管理局的药品注册批准。该药品为全球首个获批的每月给药一次的长效非典型抗精神病药，具有提高患者用药依从性、减少疾病复发风险等优势。科伦药业在中枢神经疾病领域已有多个产品获批上市，本次棕榈酸帕利哌酮注射液的获批，将进一步提升公司在中枢神经领域的管线竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400035353.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","LU2148510915.USD","002422","LU1064130708.USD","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"2582377698","title":"科伦药业（002422）披露超短期融资券获准注册，11月12日股价上涨2.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582377698","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582377698?lang=zh_cn&edition=full","pubTime":"2025-11-12 22:23","pubTimestamp":1762957401,"startTime":"0","endTime":"0","summary":"截至2025年11月12日收盘，科伦药业报收于33.13元，较前一交易日上涨2.47%，最新总市值为529.44亿元。该股当日开盘32.43元，最高33.5元，最低32.33元，成交额达5.09亿元，换手率为1.17%。公司董事会已审议通过发行非金融企业债务融资工具的议案，并经2024年年度股东大会批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111200041359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2148510915.USD","BK0060","BK0239","002422","LU1064130708.USD","LU1979443071.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"2582825471","title":"科伦药业：通过互动易平台回应市场关切","url":"https://stock-news.laohu8.com/highlight/detail?id=2582825471","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582825471?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:42","pubTimestamp":1762764130,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)11月10日在投资者关系平台上答复投资者关心的问题。投资者提问：科伦药业今年业绩大幅下滑，特别是第三季度业绩下滑的厉害，股价惨不忍睹 公司不该开业绩说明会，向广大投资者说明情况吗科伦药业回复：投资者您好，上市公司可根据具体情况确定是否召开季度业绩说明会。除业绩说明会外，公司通过互动易平台、投资者热线等渠道与广大投资者保持密切沟通，及时回应市场关切。未来，公司将进一步加强与投资者之间的交流、互动，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000020967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","BK0060","LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","002422","LU1934453819.USD","BK0239"],"gpt_icon":0},{"id":"2580780857","title":"四川科伦药业股份有限公司增持石四药集团(02005)112.8万股 每股作价约3.1港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580780857","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580780857?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:20","pubTimestamp":1762255242,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，10月31日，四川科伦药业股份有限公司增持石四药集团(02005)112.8万股，每股作价3.0978港元，总金额为349.43万港元。增持后最新持股数目约为6.8亿股，最新持股比例为23.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0060","002422","LU1934453819.USD","LU1979443071.USD","BK0239","02005","LU2460026573.USD","BK1191","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2580200938","title":"科伦药业：目前根据《深圳证券交易所股票上市规则》相关规定","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200938","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200938?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:09","pubTimestamp":1762243748,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业(002422)11月04日在投资者关系平台上答复投资者关心的问题。投资者提问：三季度业绩下降70%，没有提前预告，是否违反交易所规定？如此简单的问题贵司都不懂吗？科伦药业回复：投资者您好，目前根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指南第1号——业务办理：第四部分4.1定期报告披露相关事宜（2025年修订）》的相关规定，上市公司自愿披露季度业绩预告，不再属于强制信息披露内容，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110400023634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","LU1979443071.USD","LU2148510915.USD","BK0239","BK0060","LU1064130708.USD","LU1064131003.USD","LU1934453819.USD","399001"],"gpt_icon":0},{"id":"2580127734","title":"科伦药业（002422）2025年三季报简析：净利润同比下降51.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580127734","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580127734?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:41","pubTimestamp":1761950508,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期科伦药业发布2025年三季报。根据财报显示，科伦药业净利润同比下降51.41%。截至本报告期末，公司营业总收入132.77亿元，同比下降20.92%，归母净利润12.01亿元，同比下降51.41%。按单季度数据看，第三季度营业总收入41.93亿元，同比下降15.48%，第三季度归母净利润2.0亿元，同比下降70.18%。去年的净利率为15.41%，算上全部成本后，公司产品或服务的附加值高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2579458014","title":"科伦药业：历年分红累计超IPO融资总额","url":"https://stock-news.laohu8.com/highlight/detail?id=2579458014","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579458014?lang=zh_cn&edition=full","pubTime":"2025-10-31 16:15","pubTimestamp":1761898519,"startTime":"0","endTime":"0","summary":"证券之星消息，科伦药业10月31日在投资者关系平台上答复投资者关心的问题。公司将持续聚焦核心主业，不断提升经营业绩，为投资者创造价值。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100032744.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","LU1934453819.USD","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","002422","LU1979443071.USD","BK0239"],"gpt_icon":0},{"id":"2579144913","title":"科伦药业最新公告：前三季度净利润同比下降51.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579144913","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579144913?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:46","pubTimestamp":1761828415,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)发布2025年第三季度报告，第三季度营收为41.93亿元，同比下降15.48%；净利润为2.00亿元，同比下降70.18%。前三季度营收为132.77亿元，同比下降20.92%；净利润为12.01亿元，同比下降51.41%。业绩下滑主要由于产品销售收入及授权收入同比减少，同时联营企业投资收益下降、存货跌价准备增加等因素导致利润进一步承压。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000041443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422"],"gpt_icon":0},{"id":"2578528209","title":"科伦药业最新公告：参与全国药品集中采购拟中标","url":"https://stock-news.laohu8.com/highlight/detail?id=2578528209","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578528209?lang=zh_cn&edition=full","pubTime":"2025-10-28 20:49","pubTimestamp":1761655770,"startTime":"0","endTime":"0","summary":"科伦药业(002422.SZ)公告称，公司及子公司在国家组织的第十一批全国药品集中采购中拟中标多个产品，包括马来酸阿伐曲泊帕片、艾曲泊帕乙醇胺片、复方醋酸钠林格注射液等。预计此次中标将扩大相关产品销售，提高市场占有率，对公司未来经营业绩产生积极影响。但采购协议签订等后续事项及对公司未来业绩影响尚存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800040196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","LU2148510915.USD","002422","LU1064130708.USD","LU1064131003.USD","LU1979443071.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"2576087696","title":"科伦药业(002422.SZ)：博度曲妥珠单抗治疗2L+ HER2+乳腺癌获批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2576087696","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576087696?lang=zh_cn&edition=full","pubTime":"2025-10-17 16:57","pubTimestamp":1760691461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司控股子公司四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)靶向人类表皮生长因子受体2(HER2)的抗体偶联药物(ADC)博度曲妥珠单抗(亦称A166)(舒泰莱®)获国家药品监督管理局(NMPA)批准用于既往接受过一种或一种以上抗HER2药物治疗的不可切除或转移性HER2阳性成人乳腺癌(BC)患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ)：博度曲妥珠单抗治疗2L+ HER2+乳腺癌获批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064131003.USD","BK0239","LU2148510915.USD","002422","BK0060","LU1979443071.USD","LU1934453819.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2576081694","title":"科伦药业(002422.SZ)：罗替高汀贴片获药品注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2576081694","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576081694?lang=zh_cn&edition=full","pubTime":"2025-10-17 15:48","pubTimestamp":1760687309,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司化学药品“罗替高汀贴片”于近日获得国家药品监督管理局的药品注册批准。罗替高汀贴片是由UCB Pharma研发，2006年欧盟首获批，2018年中国批准进口，用于早期特发性帕金森病症状及体征的单药治疗，或与左旋多巴联合用于病程中的各个阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1356325.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦药业(002422.SZ)：罗替高汀贴片获药品注册批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002422","LU1979443071.USD","LU1064130708.USD","LU2148510915.USD","BK0239","BK0060","LU1064131003.USD","LU1934453819.USD"],"gpt_icon":0},{"id":"2575275950","title":"股市必读：科伦药业（002422）10月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575275950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575275950?lang=zh_cn&edition=full","pubTime":"2025-10-16 04:20","pubTimestamp":1760559619,"startTime":"0","endTime":"0","summary":"截至2025年10月15日收盘，科伦药业报收于34.8元，上涨2.32%，换手率0.92%，成交量12.02万手，成交额4.16亿元。董秘最新回复投资者： 该股近期利好不断，为何股价连续下跌？市值管理是怎么做的？市场波动属于正常现象，近期行业板块整体有调整。感谢您的关注与支持！交易信息汇总资金流向10月15日主力资金净流出56.49万元；游资资金净流入533.92万元；散户资金净流出477.43万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101600003388.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","LU2148510915.USD","LU1064131003.USD","BK0060","LU1934453819.USD","LU1064130708.USD","BK0239","LU1979443071.USD"],"gpt_icon":0},{"id":"2575298514","title":"科伦药业（002422）披露2025年度中期分红派息实施公告，10月14日股价下跌2.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575298514","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575298514?lang=zh_cn&edition=full","pubTime":"2025-10-14 17:21","pubTimestamp":1760433714,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，科伦药业报收于34.01元，较前一交易日下跌2.1%，最新总市值为543.5亿元。公司于近日发布《2025年度中期分红派息实施公告》，宣布以公司现有总股本剔除已回购股份7,272,164股后的1,590,781,208股为基数，向全体股东每10股派发现金红利1.260000元（含税），实际现金分红总额为200,438,432.2080元。股权登记日为2025年10月20日，除权除息日为2025年10月21日。本次权益分派实施后，除权除息价格按股权登记日收盘价减去每股现金红利0.1254266元计算。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400054004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1979443071.USD","LU1064131003.USD","BK0060","LU2148510915.USD","BK0239","LU1064130708.USD","002422","LU1934453819.USD"],"gpt_icon":0},{"id":"2574499462","title":"科伦药业最新公告：子公司核心产品TROP2 ADC芦康沙妥珠单抗获国家药监局批准第三项适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2574499462","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574499462?lang=zh_cn&edition=full","pubTime":"2025-10-12 16:30","pubTimestamp":1760257817,"startTime":"0","endTime":"0","summary":"科伦药业公告称，公司控股子公司科伦博泰靶向人滋养细胞表面抗原2的抗体偶联药物芦康沙妥珠单抗获国家药监局批准第三项适应症，用于治疗经表皮生长因子受体酪氨酸激酶抑制剂治疗后进展的EGFR基因突变阳性的局部晚期或转移性非鳞状非小细胞肺癌成人患者。芦康沙妥珠单抗是迄今为止全球首个且唯一对比含铂双药化疗显示出显著的总生存期获益，并且已获批用于仅接受过TKI治疗后进展的晚期NSCLC的ADC。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200005349.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002422","BK0239","LU1979443071.USD","LU1064130708.USD","LU1934453819.USD","BK0060","LU2148510915.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2574610929","title":"川宁生物新注册《科伦药业订单管理系统V1.3》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2574610929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574610929?lang=zh_cn&edition=full","pubTime":"2025-10-11 02:00","pubTimestamp":1760119248,"startTime":"0","endTime":"0","summary":"证券之星消息，近日川宁生物（301301）新注册了《科伦药业订单管理系统V1.3》项目的软件著作权。今年以来川宁生物新注册软件著作权2个，较去年同期增加了100%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了6763.37万元，同比增135%。通过天眼查大数据分析，伊犁川宁生物技术股份有限公司共对外投资了14家企业，参与招投标项目42次；财产线索方面有商标信息9条，专利信息154条，著作权信息2条；此外企业还拥有行政许可41个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101100000920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","002422","LU1934453819.USD","LU1979443071.USD","BK0239","LU1064131003.USD","LU2148510915.USD","LU1064130708.USD","301301"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1764945307755,"stockEarnings":[{"period":"1week","weight":-0.0104},{"period":"1month","weight":0.0041},{"period":"3month","weight":-0.1519},{"period":"6month","weight":-0.075},{"period":"1year","weight":0.0218},{"period":"ytd","weight":0.1581}],"compareEarnings":[{"period":"1week","weight":0.0001},{"period":"1month","weight":-0.0213},{"period":"3month","weight":0.0166},{"period":"6month","weight":0.1449},{"period":"1year","weight":0.1519},{"period":"ytd","weight":0.1563}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"四川科伦药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"37098人(较上一季度增加8.35%)","perCapita":"35201股","listingDate":"2010-06-03","address":"四川省成都市新都区新都卫星城工业开发区南二路","registeredCapital":"159805万元","survey":" 四川科伦药业股份有限公司的主营业务是大容量注射剂（输液）、小容量注射剂（水针）、注射用无菌粉针（含分装粉针及冻干粉针）、片剂、胶囊剂、颗粒剂、口服液、腹膜透析液等24种剂型药品及抗生素中间体、原料药、医药包材等产品的研发、生产和销售。公司的主要产品是输液、非输液、研发项目、其他。","listedPrice":83.36},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦药业,002422,科伦药业股票,科伦药业股票老虎,科伦药业股票老虎国际,科伦药业行情,科伦药业股票行情,科伦药业股价,科伦药业股市,科伦药业股票价格,科伦药业股票交易,科伦药业股票购买,科伦药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦药业(002422)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦药业(002422)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}